Aptamer-Imaging/Theranostic Conjugate Development Service

Introduction How Can We Help? Deliverables Key Benefits Related Products FAQs Contact

Are you currently facing challenges in achieving highly selective drug delivery or stable, quantifiable tumor imaging? Our Aptamer-Imaging / Theranostic Conjugate Development service helps you integrate precise diagnosis and targeted therapy through the assembly and optimization of high-affinity aptamers with advanced chemical linkers and payloads. We bypass the limitations of large biologics by designing small, scalable, and versatile nucleic acid structures for unparalleled therapeutic efficacy, allowing clients to transition swiftly from concept to validated lead.

Introduction of Aptamer-Imaging/Theranostic Conjugate Development

The convergence of diagnostics and therapeutics into a single, cohesive agent—Theranostics—represents the frontier of personalized medicine. This strategy requires a molecular targeting agent that is specific, small, and highly adaptable. Aptamers fulfill this role, offering biological advantages over traditional antibodies (mAbs) due to their synthetic nature and ability to be directly conjugated to multiple payloads. They are chemically synthesized, resulting in superior lot-to-lot consistency and significantly lower manufacturing costs than complex biological production. Furthermore, their small size provides faster tissue penetration, particularly into solid tumor microenvironments, and reduced toxicity compared to larger biologics.

What Is Our Service?

Our service specializes in the end-to-end development of multi-modal conjugates, using high-affinity nucleic acid aptamers as the active targeting ligand for both imaging and therapy. We design, select, chemically modify, and conjugate single-stranded DNA or RNA aptamers directly to therapeutic drugs and imaging reporters via optimized, chemically-defined linkers, creating precisely structured Aptamer-Imaging/Theranostic Conjugates.

Application Scenarios:

Targeted Oncology and Angiogenesis Inhibition: Developing ApDCs that target specific tumor markers for direct drug delivery and imaging to monitor biodistribution.
Real-Time Surgical Guidance: Creating near-infrared emitting theranostics by conjugating highly stable fluorescent probes to the aptamer, enabling surgeons to visualize tumor margins with high precision during excision.
Controlled, Smart Drug Release: Engineering systems with microenvironment-sensitive cleavable chemical linkers to trigger a predictable release of the therapeutic payload in response to specific tumor cues.

Why Choose Us?

We resolve critical pain points associated with developing advanced targeted therapeutics by transforming scientific challenges into scalable commercial benefits.

Pain Points	Benefit Created by Creative Biolabs
Poor Tumor Penetration	Our ApDCs are significantly smaller than antibodies, ensuring superior diffusion and faster tumor uptake for rapid diagnostic feedback and drug efficacy.
Systemic Toxicity	We employ aptamer-mediated active targeting combined with cleavable, tumor-microenvironment sensitive linkers, ensuring the drug is liberated primarily within the targeted cell or tumor environment.
High Development Cost & Variability	We use chemical synthesis for all components (aptamer, linkers, conjugation), guaranteeing high purity, zero batch variability, and cost-effective scale-up for clinical supply.

Aptamer-based probes for molecular imaging. (OA Literature) Fig.1 Molecular imaging with aptamer-enhanced probes.¹

How Creative Biolabs' Aptamer-Imaging/Theranostic Conjugate Development Can Assist Your Project?

Our service provides a clear pathway from target identification to a fully validated theranostic lead candidate ready for preclinical assessment.

Workflow

Required Starting Materials
- Target Biomarker
- Therapeutic Payload
- Imaging Modality Preference
Aptamer Selection & Stabilization
Payload and Reporter Functionalization
ApDC Cleavable Linker Design & Conjugation
Microenvironment-Triggered Release Testing
Biological Validation

Realize Your Project's Strength – Inquire About Pricing and Availability Now!

Deliverables

Upon completion of the project, Creative Biolabs provides a complete documentation package and final product formulation, ensuring a seamless transition to the next phase of development:

Finalized Aptamer Sequence and Modification Strategy Report: Detailed document covering the selected sequence, chemical modifications, and PEGylation strategy used.
Cleavable Linker Design and Stoichiometry Report: Specific details on the linker chemistry and the confirmed drug-to-aptamer ratio.
Full Physicochemical Characterization Data: Raw data and analysis for spectroscopic confirmation, purity, and stability of the final conjugate, confirming chemical identity.
In Vitro Efficacy and Selectivity Lab Report: Comprehensive data including affinity binding, Cell Uptake/Fluorescence Microscopy images, and comparative cytotoxicity on positive and negative cell lines.
Quantified Controlled Release Profile Data: Statistical comparison of drug release kinetics under tumor-relevant conditions versus physiological conditions.

Key Benefits

Creative Biolabs' expertise in integrating aptamer technology with advanced chemical conjugation offers distinct advantages critical for success in theranostic development:

Superior Imaging & Diagnosis

Our use of stable reporters provides unparalleled signal brightness and photostability, delivering high-sensitivity, quantifiable data essential for both non-invasive diagnosis and intraoperative tumor margin visualization.

Precision and Smart Delivery

We engineer multi-functional systems using microenvironment-sensitive cleavable linkers. This ensures the therapeutic payload is activated and released only upon encountering specific tumor conditions, significantly boosting efficacy and minimizing systemic toxicity.

Chemically Defined Stoichiometry

Unlike complex nanocarrier systems, direct conjugation provides a fully chemically defined drug-to-aptamer ratio. This allows for precise and consistent dosing, which is critical for successful translation into clinical trials.

Harness the Creative Biolabs Edge – Request Your Quote Now!

Related Products

Aptamer Products List

Frequently Asked Questions

Q1: How do these aptamer conjugates compare to using traditional mAbs for targeting?

A: Aptamers offer several key advantages: they are significantly smaller, allowing for deeper and faster tumor penetration; they are chemically synthesized, resulting in lower production costs and greater batch consistency; and they are non-immunogenic, reducing the risk of adverse immune reactions.

Q2: What is the typical timeframe and complexity for scaling up the final conjugate for preclinical testing?

A: A major advantage of our approach is the reliance on purely chemical synthesis for all components (aptamer, linker, and conjugate). This allows the scale-up process to be highly predictable, cost-effective, and rapid. We provide a validated, standardized protocol designed specifically for industrial-level manufacturing.

Q3: What if our target biomarker is difficult or has historically failed to produce high-affinity binders?

A: Our expertise lies in overcoming these exact challenges. We utilize advanced selection methodologies, including gene-modified Cell-SELEX and specialized libraries, which can successfully identify high-affinity aptamers even against complex or native-state membrane proteins.

Contact Us

Creative Biolabs' Aptamer-Imaging/Theranostic Conjugate Development service offers an integrated solution for the next generation of targeted medicine. By combining the high affinity and chemical stability of aptamers with precision-engineered cleavable linkers and imaging agents, we deliver systems capable of highly specific diagnosis, controlled payload release, and superior therapeutic efficacy. Our commitment is to provide de-risked, scalable lead candidates that accelerate your clinical pipeline. Ready to revolutionize your drug delivery and diagnostic platform? Contact our dedicated scientific solutions team today to discuss your project requirements and receive a personalized quote.

Reference

Bohrmann, Lennart, et al. "Aptamers used for molecular imaging and theranostics-recent developments." Theranostics 12.9 (2022): 4010. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.7150/thno.72949.

For Research Use Only.